Description: biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery platform, the company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases.
Home Page: www.bioasis.us
157 Church Street
New Haven,
CT
06510
United States
Phone:
203 533 7082
Officers
| Name | Title |
|---|---|
| Dr. Deborah Ann Rathjen B.Sc. (Hons.), FTSE, M.A.I.C.D., Ph.D., Q.C. | Exec. Chairman, CEO & Pres |
| Mr. Dave Jenkins | Chief Financial Officer |
| Mr. Graeme Dick | Director of Investor Relations |
| Mr. Kim Elton | Director of Marketing |
| Mr. Doug Williams MBA | Exec. VP & Chief Bus. Officer |
| Dr. Mei Mei Tian | VP & Head of External Research |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 53.4668 |
| Price-to-Sales TTM: | 26.5207 |
| IPO Date: | |
| Fiscal Year End: | February |
| Full Time Employees: | 0 |